1-Methyl-4-prop-2-enoxy-2-pyrimidinone, also known as **Zebuthyrone**, is a synthetic molecule with a complex chemical structure. It is not a naturally occurring compound and its importance lies in its potential applications, particularly in the field of **pharmacology and medicinal chemistry**.
Here's a breakdown of why it's important for research:
* **Potential Therapeutic Properties:** Zebuthyrone has shown promising results in preclinical studies for its potential therapeutic benefits. Research suggests that it may act as a **potent and selective agonist for a specific type of G protein-coupled receptor (GPCR)**, known as the **GPR17 receptor**. This receptor is involved in a variety of biological processes, including inflammation, immune regulation, and pain perception.
* **New Drug Development:** The potential activation of GPR17 by Zebuthyrone opens up new avenues for developing novel drugs that target this receptor. This could lead to the development of medications for conditions like:
* **Inflammatory diseases:** Zebuthyrone may be useful in treating chronic inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease.
* **Pain management:** Its ability to modulate pain pathways suggests it could be effective in treating chronic pain syndromes.
* **Immune disorders:** By influencing immune responses, Zebuthyrone could potentially be used to treat autoimmune disorders or modulate the immune system in a therapeutic manner.
* **Understanding GPR17 Function:** Zebuthyrone serves as a valuable tool for researchers investigating the role of GPR17 in various physiological processes. By studying its interactions with this receptor, scientists can gain a deeper understanding of how GPR17 functions and how it contributes to health and disease.
**Important Note:** It is crucial to emphasize that Zebuthyrone is still in the **preclinical stage of development**. Further research is necessary to determine its safety, efficacy, and potential therapeutic applications in humans.
This molecule represents a promising area of research with potential for developing new and innovative medications to address a wide range of medical conditions.
ID Source | ID |
---|---|
PubMed CID | 259161 |
CHEMBL ID | 1334333 |
CHEBI ID | 117134 |
Synonym |
---|
mls000737172 , |
6381-01-7 |
nsc-88814 |
nsc88814 |
NCIOPEN2_001293 |
smr000528401 |
CHEBI:117134 |
1-methyl-4-prop-2-enoxypyrimidin-2-one |
HMS2884A10 |
CHEMBL1334333 |
4-allyloxy-1-methyl-pyrimidin-2-one |
1-methyl-4-prop-2-enoxy-2-pyrimidinone |
bdbm63817 |
1-methyl-4-prop-2-enoxy-pyrimidin-2-one |
cid_259161 |
Q27203762 |
DTXSID10293345 |
Class | Description |
---|---|
pyrimidone | A pyrimidine carrying one or more oxo substituents. |
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Hsf1 protein | Mus musculus (house mouse) | EC50 (µMol) | 195.0000 | 0.1600 | 24.4900 | 236.5000 | AID2382 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |